The global Drugs of Abuse (DOA) Testing Market research report 2030, as published by Data bridge Market Research, provides insights into the current global outlook and key regions, examining Major Players, Countries, Product Types, and end industries. It focuses on top players in the global market and categorizes the market based on several parameters.

This Drugs of Abuse (DOA) Testing market research report identifies the competitive landscape of industries, offering a comprehensive understanding of international competition. The study outlines the anticipated growth of the global market during forecast period. Compiled with a blend of static and dynamic perspectives, this research report captures the essence of the businesses views.

Data Bridge Market Research analyses that the drugs of abuse (DOA) testing market, which is USD 6253.25 million in 2022, is expected to reach USD 13650.06 million by 2030, at a CAGR of 10.25% during the forecast period 2023 to 2030.

Top Companies in the Global Drugs of Abuse (DOA) Testing Market:
Some of the major players operating in the drugs of abuse (DOA) testing market are:

Takeda Pharmaceutical Company Limited (Japan)

F. Hoffmann-La Roche Ltd (Switzerland)

Abbott (U.S.)

Medtronic (Ireland)

Abbott (U.S.)

BD (U.S.)

Johnson & Johnson Services, Inc. (U.S.)

GSK Plc. (U.K.)

Bayer AG (Germany)

Zimmer Biomet (U.S.)

Stryker Corporation (U.S.)

Homology Medicines, Inc (U.S.)

Novartis AG (Switzerland)

Pfizer Inc. (U.S.)

JCR Pharmaceuticals Co., Ltd. (Japan)

Sangamo Therapeutics (U.S.)

AVROBIO, Inc (U.S.)

REGENXBIO Inc (U.S)

CANbridge Life Sciences Ltd. (Taiwan)

Denali Therapeutics (U.S.)

Jasper Therapeutics, Inc. (U.S.), among others.

Market Segmentation:

Drugs of Abuse (DOA) Testing Market Dynamics

Drivers

Increase in consumption and trade of illicit drugs

The increased production, consumption, and trade of new and illicit drugs will result in a high demand for DoA testing, driving industry growth. According to the United Nations Office on Drugs and Crime's World Drug Report 2017, the annual prevalence of all illicit drug use is 5.3%, with 255 million users in 2015. This will necessitate the need for DOA testing, propelling the market forward. The government's initiatives to raise awareness about DOA and increase organizational compliance for DOA testing will contribute to the overall market's growth. The high demand for products with increased specificity and sensitivity to designer drugs will also contribute to the industry's growth.

Technological advancements and product portfolio expansion

To maintain their competency and market share, leading players in the DoA testing market are expanding their product portfolio through product additions and software updates with new substances for DoA testing. For instance, Shimadzu Corporation, released its Smart Forensic Database Ver. 2 in February 2018, with features for analysing forensic toxicological substances involved in DoA in biological samples using Gas Chromatograph-Mass Spectrometry. Similarly, Thermo Fisher Scientific Inc. updated its library for the Thermo Scientific TruNarc handheld narcotics analyzer in November 2017. The update added 45 new substances to the handheld narcotics analyzer, including 14 new forms of fentanyl, and it can now detect Carfentanil.

Opportunities

Rising ageing population

According to data published by the Organization for Economic Cooperation and Development (OECD) in 2020, nearly one-third of adults in the European Union aged 15-64, or approximately 97 million people, have used illicit drugs at some point in their lives, with men reporting drug use more frequently than women. To maintain their competency and market shares, leading players in the drug abuse testing market are expanding their product portfolios by adding new products and updating software with new substances for drug abuse testing. These are the certain reasons for propelling the market growth.

Restraints/Challenges

Inability of testing products to detect small amounts of special drugs

The inability of these testing products to detect small amounts of special drugs is expected to hamper the market growth. In the forecast period of 2023-2030, the transformation of laws to legalize the use of recreational drugs/illicit drugs is expected to challenge the drugs of abuse (DOA) testing market.

This drugs of abuse (DOA) testing market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the drugs of abuse (DOA) testing market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Recent Developments

In 2020, WellCare Health Plans introduced new clinical coverage guidelines and claims payment policy for urine drug testing, including definitive urine drug testing as medically necessary as part of a routine monitoring programme for individuals receiving treatment for chronic pain with prescription opioid or other potentially abused medications, or those undergoing treatment for, or monitoring for relapse of, opioid addiction or substance use disorder.

In 2022, the Delaware Division of Public Health began including fentanyl strips in Narcan kits for public distribution. The initiative was part of a harm-reduction strategy aimed at preventing accidental fentanyl overdoses.

Geographically, the detailed analysis of consumption, revenue, market share, and growth rate of the following regions:

– Middle East and Africa (South Africa, Saudi Arabia, UAE, Israel, Egypt, etc.)

– North America (United States, Mexico & Canada)

– South America (Brazil, Venezuela, Argentina, Ecuador, Peru, Colombia, etc.)

– Europe (Turkey, Spain, Turkey, Netherlands Denmark, Belgium, Switzerland, Germany, Russia UK, Italy, France, etc.)

– Asia-Pacific (Taiwan, Hong Kong, Singapore, Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia).

Browse The Report Description:

https://www.databridgemarketresearch.com/reports/global-drugs-of-abuse-doa-testing-market

Strategic Points from Table of Content:

– Market Summary

– Economic Impact Competition Analysis by Players

– Production, Revenue (Value) by geographical segmentation

– Drugs of Abuse (DOA) Testing Market Size by Type and Application

– Regional Market Status and Outlook

– Drugs of Abuse (DOA) Testing Market Analysis and Outlook

– Drugs of Abuse (DOA) Testing Market Forecast by Region, Type, and Application

– Cost Investigation, Market Dynamics

– Marketing Strategy comprehension, Distributors and Traders

– Market Effect Factor Analysis

– Research Finding/ Conclusion

– Appendix

Browse Other Trending Reports:

Global Drugs of Abuse (DOA) Testing Market – Industry Trends and Forecast to 2030
https://www.databridgemarketresearch.com/reports/global-drugs-of-abuse-doa-testing-market 

Global Seed Coating Materials Market -  Industry Trends and Forecast to 2029
https://www.databridgemarketresearch.com/reports/global-seed-coating-materials-market 

Global Thermistor Market - Industry Trends and Forecast to 2029
https://www.databridgemarketresearch.com/reports/global-thermistor-market

About Us:
Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market.

Contact Us:
Data Bridge Market Research
Tel: +1-888-389.80-2818 | +44 208 089 1725 | +852 8192 7475
Email: Corporatesales@databridgemarketresearch.com